JSON
Sturchio A, Paslawski W, Khosousi S, Markaki I, Nalls MA, Singleton AB, Iwaki H, Svenningsson P
Mov Disord Clin Pract - (-) - [2025-09-24; online 2025-09-24]
DOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) is an emerging Parkinson's disease (PD) biomarker, but its association with nonmotor symptoms is unclear. We aimed to determine if baseline DDC was associated with future cognitive decline in PD. We correlated baseline CSF DDC, detected using the proximity extension assay, with Montreal Cognitive Assessment (MoCA) score using longitudinal data from 3 cohorts: Biopark, PPMI, and PDBP. DDC was significantly associated with cognitive decline in both the Biopark cohort (P-value < 0.0001) and the PDBP/PPMI cohorts (P-value < 0.0001). The results were still significant after correcting for levodopa-equivalent daily dose in the Biopark cohort (P-value < 0.0001) and when the analysis was restricted to the de novo subjects, both in Biopark (P-value: 0.0065) and PPMI (P-value<0.0001) cohorts. CSF DDC is a potential biomarker for the prediction of cognitive decline in PD patients.
Affinity Proteomics Stockholm [Service]
PubMed 40990085
DOI 10.1002/mdc3.70367
Crossref 10.1002/mdc3.70367